کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2136407 1547905 2016 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy
ترجمه فارسی عنوان
مرگ و میر مرتبط با بیماری در بیماران مبتلا به لوسمی میلوئید مزمن در درمان دوم یا بالاتر از مرگ و میر مربوط به درمان
کلمات کلیدی
لوسمی میلوئیدی مزمن، فاز مزمن، مرگ و میر پیشرفت بیماری، عوارض جانبی مرتبط با درمان
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


• We compared death due to disease progression and treatment-related AEs in CP-CML.
• Relevant studies were identified by systematic literature review.
• Disease progression causes 10 times deaths as treatment-related AEs in CP-CML.
• Excessive deaths in CP-CML on later line therapy as compared to US census estimates.
• Benefits of effective treatment outweigh risks of treatment-related mortality.

Treatment of newly-diagnosed patients with chronic-phase chronic myeloid leukemia (CP-CML) with tyrosine kinase inhibitors (TKIs) results in near-normal life expectancy. However, CP-CML patients resistant to initial TKIs face a poorer prognosis and significantly higher CML-related mortality. We conducted a systematic literature review to evaluate the specific causes of deaths (diseases progression versus drug-related) in CP-CML patients receiving second- or third-line therapy. We identified eight studies based on our criteria that reported causes of death. Overall, 5% of second-line and 10% of third-line patients died during the study follow-up period. For second-line, (7 studies, n = 1926), mortality was attributed to disease progression for 41% of deaths, 2% to treatment-related causes, 3% were treatment-unrelated, and 50% were unspecified adverse events (AEs), not likely related to study drug. In third-line, (2 studies, n = 144), 71% deaths were attributed to disease progression, 7% treatment-related AEs, 14% treatment-unrelated and 7% unspecified AEs. Annual death rates for second- and third-line therapy were significantly higher than for general population in similar age group. Our findings suggest death attributed to disease progression is approximately 10 times that due to treatment-related AEs in patients with CP-CML receiving second- or third-line therapy. Therefore, the potential benefits of effective treatment for these patients with the currently available TKIs outweigh the risks of treatment-induced AEs.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 43, April 2016, Pages 1–8
نویسندگان
, , , , , , ,